D DetectCancer.orgIndependent detection hub

Cancer detection, without the sales fog

Finding cancer is not enough. The test has to help people live better or longer.

DetectCancer.org is the hub for a family of disease detection guides: symptoms not to ignore, who is at risk, what screening can actually prove, how biopsy and histology confirm disease, and where new blood tests or full-body MRI may help or harm.

Open live guides New blood tests Judge the evidence TheCancers.com
Educational, not personal medical advice. This site is independent and is not affiliated with any commercial multi-cancer blood-test company. Use it to prepare for a clinician discussion, especially when a test result, symptom or family history creates a real decision.
Screen

when a test has a reasonable chance of finding treatable disease or preventing cancer.

Confirm

with imaging, endoscopy, biopsy, cytology, histology or genetics when suspicion is real.

Measure

stage III/IV disease, cancer-specific mortality, all-cause mortality, anxiety and overdiagnosis.

Avoid

false reassurance from a weak negative test and cascades from false positives.

Live guides

The first spokes in the detection cluster.

These pages go deeper than a simple symptoms list. Each one covers risk, red flags, screening, diagnostic confirmation, histology, follow-up, trial evidence, harms and sensible crosslinks.

Removed colon polyp specimen after colonoscopy

Colon cancer detection

FOBT, FIT, stool DNA, colonoscopy quality, cecal intubation, bowel prep, AI-assisted colonoscopy, polyp histology and surveillance intervals.

Open guide Doctor explaining prostate cancer detection and treatment options

Prostate cancer detection

PSA, repeat PSA, MRI, DRE context, transperineal biopsy, Gleason grade, staging and modern active surveillance versus treatment decisions.

Open guide Mammogram image showing breast cancer

Breast cancer detection

Mammography, ultrasound, MRI, dense breasts, BI-RADS, biopsy, histology, receptors, genetics, inflammatory cancer and screening tradeoffs.

Open guide Pancreatic cancer detection and treatment visual

Pancreatic cancer detection

Symptoms, jaundice, new diabetes, genetics, high-risk surveillance, CA19-9 limits, CT, MRI/MRCP, EUS biopsy and cyst controversy.

Open guide CT-style kidney mass visual

Kidney cancer detection

Blood in urine, incidental renal masses, ultrasound, CT renal mass protocol, MRI, biopsy, Bosniak cysts and hereditary risk.

Open guide Liver cancer cross-sectional imaging

Liver cancer detection

Cirrhosis surveillance, hepatitis B and C risk, ultrasound, AFP, liver-protocol CT/MRI, biopsy and cholangiocarcinoma overlap.

Open guide CT image of lung adenocarcinoma

Lung cancer detection

Low-dose CT, smoking risk, pulmonary nodules, PET-CT, bronchoscopy, EBUS, CT-guided biopsy and sputum/blood test caveats.

Open guide Upper endoscopy visual for stomach cancer detection

Stomach cancer detection

Alarm symptoms, H. pylori, endoscopy, biopsy, intestinal metaplasia, CDH1 hereditary risk, CT, EUS and screening countries.

Open guide Ultrasound image of papillary thyroid carcinoma

Thyroid cancer detection

Neck lumps, ultrasound risk patterns, FNA cytology, molecular tests, medullary markers, MEN2 genetics and overdiagnosis.

Open guide MRI image of glioblastoma

Brain cancer detection

Seizures, headaches with red flags, MRI, CT emergencies, biopsy, resection histology, glioma molecular pathology and liquid biopsy limits.

Open guide

How to judge a detection test

A good cancer test is not simply one that finds more abnormalities.

The crucial question is whether testing improves outcomes enough to justify false positives, overdiagnosis, cost, procedures and anxiety. That standard is stricter for population screening than for an individual with symptoms or high inherited risk.

1

Analytic validity

Does the lab measure what it claims reliably?

2

Clinical accuracy

Sensitivity, specificity, positive predictive value and false negatives in the intended population.

3

Stage shift

Does testing reduce stage III/IV cancers, not just create more early labels?

4

Mortality

Does it reduce cancer-specific deaths, and ideally all-cause mortality?

5

Net value

Does the benefit justify follow-up scans, biopsies, treatment, anxiety and health-system load?

Colonoscopy image of colon polyps
Endoscopic tests can detect and sometimes remove the precursor lesion.
Colon adenocarcinoma histology slide
For most cancers, tissue diagnosis remains the final word.
CT image of colorectal liver metastases
Late-stage disease is what screening programs are trying to prevent.
Blood tube for laboratory testing
Blood tests are useful, but a positive screening signal often starts a cascade.

New tests, old problem

Multi-cancer blood tests and full-body MRI may become important, but broad population use needs harder evidence.

The promise is obvious: one blood draw or scan might reveal a hidden pancreatic, ovarian, brain, kidney, sarcoma or other hard-to-detect cancer before symptoms. The risk is equally obvious: false positives, incidental findings, extra investigations, delayed reassurance, overdiagnosis and expensive anxiety.

Promising but contested

Multi-cancer early detection blood tests

These tests look for tumor-derived DNA methylation, fragments, mutations or other signals in blood. They may be most attractive for cancers with no good screening test, but average-risk population screening needs proof that it changes meaningful outcomes.

  • High specificity can still produce many false positives when the pre-test cancer probability is low.
  • A positive result may lead to CT, PET, MRI, endoscopy, biopsy or months of surveillance.
  • A negative result should not replace proven screening such as FIT/colonoscopy, mammography, cervical HPV testing or lung CT in eligible smokers.
  • Insurance coverage is variable, and self-paid testing can shift costs downstream to the patient and health system.
Useful in selected people

Whole-body MRI

Whole-body MRI avoids ionizing radiation and can reveal silent tumors, inflammatory disease, marrow lesions or aneurysms. It can also find tiny lesions that are common, harmless or impossible to classify without repeated scans.

  • Best established in specific high-risk syndromes or defined clinical questions, not universal annual screening.
  • Incidental aneurysms may be a blessing if follow-up prevents rupture, or a long anxiety loop if too small for repair.
  • For aneurysm detail, see DetectAneurysm.com and IntracranialAneurysm.com.
  • The Kim Kardashian aneurysm story is a public example of this dilemma: better to know and control blood pressure/smoking, or worse to carry the worry?

The sensible middle position

These technologies are not a scam merely because they are early, and they are not a public-health answer merely because they are exciting. Individuals may choose them after understanding the uncertainty. Governments and insurers need stronger evidence before broad introduction: fewer late cancers, fewer deaths, acceptable false positives, clear diagnostic pathways and affordable downstream care.

What still works

Site-specific screening remains the backbone.

The next pages should make the distinction clear: screening is for people without symptoms; diagnosis is for a sign, symptom, abnormal test or high-risk history.

CancerUseful detection routesKey trap
Colon and rectalFIT/FOBT, stool DNA-FIT, colonoscopy, polyp histology, CT colonography in selected people.A negative stool test does not explain symptoms; a poor prep colonoscopy may need early repeat.
BreastMammography, tomosynthesis, ultrasound, MRI in high-risk patients, core needle biopsy, excision and histology.Dense breasts and indeterminate imaging can create both missed cancers and false positives.
ProstatePSA, repeat PSA, PSA density, MRI, selective DRE, transperineal biopsy, histology and genomic tests in selected cases.Finding low-risk cancer is not the same as needing aggressive treatment.
LungLow-dose CT for eligible smokers, CT follow-up, bronchoscopy/EBUS, sputum or blood tests mainly investigational.Small nodules are common; the danger is both missed early disease and over-investigation.
KidneyHematuria workup, ultrasound, CT renal mass protocol, MRI, selective biopsy and inherited-risk surveillance.Small renal masses and cysts are common; not every finding needs aggressive treatment.
LiverCirrhosis and hepatitis-risk surveillance with ultrasound/AFP, then multiphase CT or MRI.Average-risk screening is not the same as high-risk HCC surveillance.
StomachAlarm-symptom endoscopy, biopsy, H. pylori testing, premalignant surveillance and high-incidence country programs.Indigestion is common, but anemia, weight loss, vomiting or black stools should not be dismissed.
ThyroidNeck exam, ultrasound risk scoring, FNA cytology, molecular tests and calcitonin/RET where relevant.Screening can find many harmless tiny cancers and cause overtreatment.
BrainMRI with contrast, urgent CT for emergencies, spectroscopy/perfusion in selected cases, biopsy or resection histology.There is no general screening test; symptoms and high-risk syndromes drive imaging.
CervicalHPV testing, Pap cytology, colposcopy, biopsy, vaccination history and follow-up of abnormalities.HPV positivity is common and often clears; high-grade lesions need proper tracking.
Ovarian and pancreaticHigh-risk genetics, symptom-led imaging, CA-125 or ultrasound in context, MRI/EUS for pancreatic risk programs.Average-risk screening remains hard because false positives and late detection dominate.

Cluster roadmap

Built as a hub for the other cancer detection pages.

Live pages link strongly. Planned pages are named here without pretending they are done. As each guide is created, it can inherit the same evidence structure and add disease-specific reviews and clinical trial links.

Colon cancer

Live: FIT, colonoscopy, polyps, biopsy, staging.

Breast cancer

Live: mammography, ultrasound, MRI, biopsy, genetics.

Lung cancer

Live: low-dose CT, nodules, sputum/saliva research, bronchoscopy.

Ovarian cancer

Live: symptoms, CA-125, ultrasound, genetics, high-risk screening controversy.

Pancreatic cancer

Live: high-risk MRI/EUS surveillance, symptoms, CT, CA19-9 limits and biopsy.

Thyroid cancer

Live: ultrasound, FNA cytology, molecular tests and overdiagnosis.

Brain cancer

Live: MRI, urgent CT, biopsy, histology and molecular pathology.

Melanoma and skin cancer

Live: skin checks, dermoscopy, biopsy, sentinel nodes, SCC/BCC and AI/app caveats.

Testicular cancer

Live: self-awareness, ultrasound, AFP, hCG, LDH and orchiectomy histology.

Genes and inherited risk

BRCA, Lynch, FAP, polyposis, cascade testing and counseling.

Non-cancer detection

Alzheimer's, aneurysm, heart disease, stroke, sepsis and other planned guides.
TheCancers.com TheTreatments.com 50Tests.com 50yrsold.com Anonamed

Source spine

Every disease page should carry a few strong sources, not a swamp of links.

This hub uses broad sources now. Each individual cancer guide should add one disease overview review, one screening review or guideline, and clinical trials links for detection research.

USPSTF screening recommendationsUS preventive screening recommendations for cancer and other conditions. Lancet MCED cautionary commentaryRecent argument for careful trials before broad multi-cancer blood-test introduction. NHS-Galleri performance resultsRandomized population trial evidence for a multi-cancer early detection test. FDA Shield approvalBlood-based colorectal cancer screening approval and device documentation. NCI on ShieldPlain-language discussion of CRC blood-test sensitivity, specificity and precancer detection. ClinicalTrials.gov detection trialsSearchable trial registry for cancer screening and diagnostic-test research.